Form 4: Immunome Chief Legal Officer Granted Significant Stock Options

Immunome Inc.'s Chief Legal Officer and General Counsel, Sandra G. Stoneman, was granted 190,000 employee stock options with an exercise price of $10.6 per share.

Summary

• Sandra G. Stoneman, Immunome Inc.'s Chief Legal Officer & General Counsel, was granted 190,000 employee stock options.
• The options have an exercise price of $10.6 per share.
• The grant date for these options was July 29, 2025.
• The options begin vesting on July 29, 2026, with 25% of the shares vesting on this date.
• Following the initial vesting, one-thirty-sixth (1/36th) of the remaining shares will vest every month thereafter.
• The options are set to expire on July 28, 2035.
• Following this transaction, Sandra G. Stoneman beneficially owns 190,000 derivative securities (employee stock options).

Sentiment

Score: 7

Explanation: The filing indicates a positive alignment of executive incentives with shareholder interests through a standard compensation mechanism. It does not, however, provide new information on operational performance or strategic shifts.

Positives

• The grant of 190,000 employee stock options to a key executive like the Chief Legal Officer aligns management's long-term interests with those of shareholders.
• The options incentivize the executive to contribute to the company's stock price appreciation, as the options become more valuable if the stock price rises above the $10.6 exercise price.

Future Outlook

The grant of stock options is a standard component of executive compensation, designed to incentivize long-term performance and retention. It implies a continued commitment of the executive to the company's future success.

Industry Context

The grant of employee stock options is a common and widely accepted practice in the biotechnology and pharmaceutical industries for executive compensation. It serves to attract, retain, and motivate key personnel by linking their financial success directly to the company's share price performance.

Comparison to Industry Standards

• The structure of the option grant, including the vesting schedule (initial cliff followed by monthly vesting), is typical for executive compensation packages in the biotech sector, aiming to foster long-term commitment.
• The exercise price being set at the market price on the grant date is standard for incentive stock options.

Related Party Transactions

• Grant of 190,000 employee stock options to Sandra G. Stoneman, Chief Legal Officer & General Counsel, as part of her compensation package, which is a transaction between the company and a related party (an executive).

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with shareholder value creation.
• Employees: May signal stability and a commitment to executive retention, potentially boosting morale.

Next Steps

• The options will continue to vest according to the specified schedule, with the first 25% vesting on July 29, 2026.
• The executive may choose to exercise vested options at any point before their expiration date of July 28, 2035, subject to company policy and blackout periods.

Key Dates

Recommendation

This Form 4 filing reports a standard executive compensation event, specifically the grant of stock options to the Chief Legal Officer. While this action aligns management incentives with shareholder interests, it does not introduce new fundamental information about the company's financial performance, strategic direction, or operational outlook that would warrant a change in investment recommendation based solely on this filing.

Keywords

Immunome, IMNM, Stock Option, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Sandra Stoneman